Company intelligence / Profile preview

Mido

Ownership: Private
Development stage: Other

Overview

Mido is an early-stage biotechnology company focused on developing innovative drug delivery systems and medical devices for metabolic health. The company's primary focus is on creating smart, patient-centric solutions for the management of chronic conditions such as diabetes. Mido's technology aims to improve the precision and ease of drug administration, potentially enhancing patient adherence and therapeutic outcomes. By integrating advanced materials with digital health capabilities, Mido seeks to redefine the standard of care in metabolic disease management.

Therapeutic areas: EndocrinologyMetabolic Disorders
Modalities: DeviceSmall molecule
Industry: Biotech

Beyond the preview

Go deeper on Mido.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mido.

Explore the full profile